Journey Mapping of the Patient Experience from Diagnosis to End of Life in Lung Cancer: A Qualitative Meta-Synthesis.

Semin Oncol NursJun 18, 2026 (epub)

Fanyun Zhang, Yuanqi Wang, Yalin Xiao et al.

✦ AI-curated · Sources linked

In 30 seconds

This qualitative meta-synthesis examined the experiences of lung cancer patients from diagnosis to end of life, analyzing 13 studies. The research identified four stages in the patient journey: evaluation and diagnosis, initial treatment, maintenance therapy, and end-of-life, revealing 30 themes related to tasks, emotions, and pain points. The findings emphasize the complexity of patient experiences and the need for tailored management strategies.

Key findings

  • The lung cancer patient journey includes four stages: evaluation and diagnosis, initial treatment, maintenance therapy, and end-of-life.
  • A total of 30 themes emerged across three dimensions: tasks, emotions, and pain points.
  • Each stage consists of 2-3 themes that highlight stage-specific needs and challenges.

Why it matters

Understanding the patient journey in lung cancer is crucial for developing comprehensive management strategies that address specific needs at each stage, ultimately improving patient outcomes and quality of life.

Source

Published in Semin Oncol Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.